BACKGROUND: Prolonged retention of antibiotic-loaded articulating spacers after the first stage of a two-stage revision for periprosthetic joint infection (PJI) can occur because of patient preference, surgeon preference, or medical reasons that prevent the planned second stage. Little is known about the frequency of persistent infections, mechanical complications, and functional results in patients with retained spacers. QUESTIONS/PURPOSES: At a minimum follow-up of 2 years after spacer placement, among patients who do not undergo the second stage revision (replacement of the spacer with a definitive prosthesis of the hip or knee): (1) What was the survival of the spacer free from unplanned reoperation or removal, the cumulative incidence of symptomatic infection, and the overall (Kaplan-Meier) survivorship of the patients? (2) What is the cumulative incidence of mechanical complications (spacer fracture or dislocation)? (3) What is the ambulatory status of patients who have retained their spacers? METHODS: Between March 2011 and July 2023, a total of 111 and 152 patients underwent first-stage revision with an articulating spacer placement as part of a planned two-stage procedure for chronic PJI after THA and TKA at our institution, respectively. Of these, 21% (23 of 111) in the THA group and 24% (37 of 152) in the TKA group did not undergo the anticipated second-stage reimplantation at our institution at least 1 year after spacer placement. Among the original cohorts, 2% (2 of 111) of patients who underwent THA and 3% (4 of 152) of patients who underwent TKA subsequently underwent second-stage reimplantation at outside institutions when reviewed, leaving 19% (21 of 111) in the THA group and 22% (33 of 152) in the TKA group with retained spacers. Of the original cohorts, 7% (8 of 111) in the THA group and 5% (8 of 152) in the TKA group did not have a 2-year follow-up, leaving 12% (13 of 111) of patients with THA and 16% (25 of 152) of patients with TKA available for analysis with a minimum of 2 years of follow-up or death in this retrospective study. The median (range) follow-up from spacer placement to the latest follow-up was 5 years (2 to 11) for patients with THA and 4 years (2 to 8) for patients with TKA. In the THA cohort, the median (range) age was 72 years (59 to 86), and eight patients were female; the median BMI was 32 kg/m2, and the median Charlson comorbidity index (CCI) was 3.5. In the TKA cohort, the median (range) age was 69 years (45 to 83), 13 patients were female, the median BMI was 31 kg/m2, and the median CCI was 4. Complication data following spacer placement were obtained from the electronic medical record and by telephone follow-up when needed. Clinical symptoms (swelling, erythema, warmth, fever, drainage, sinus tract, and pain), inflammatory markers (C-reactive protein and erythrocyte sedimentation rate), available radiographic findings, and laboratory test results (including synovial fluid analysis when obtained) were reviewed for evidence of infection or spacer-related mechanical failure. Infection after the spacer placement was defined as failure when the treating surgeon determined that an unplanned return to the operating room or spacer removal was warranted, acknowledging that postoperative evaluation thresholds varied among surgeons. Spacer-related mechanical failure was defined as spacer fracture or dislocation leading to reoperation or spacer removal. Patients were classified based on whether they underwent an unplanned reoperation or spacer removal. Patients who did not undergo unplanned reoperation or spacer removal were further categorized based on use of chronic suppressive antibiotics (decisions regarding chronic antibiotic therapy were made by the treating surgeon and/or infectious disease team). Patients who underwent reoperation were those who returned to the operating room because of concerning clinical, imaging, and/or laboratory findings of infection or mechanical complications, and the treating surgeon decided to proceed with revision surgery. All reoperation decisions were made by fellowship-trained arthroplasty surgeons with high-volume experience in two-stage revision. We used a competing-risks model to estimate survival of the spacer free from unplanned reoperation or removal attributable to infection or mechanical complications (calculated as 1 minus the corresponding cumulative incidence), with death treated as a competing event. Kaplan-Meier analysis was used to estimate patient survivorship, with death as the endpoint. Mortality data were obtained from medical records and hospital databases and were confirmed by telephone follow-up with family members and public records when needed. Ambulatory status before and after spacer placement was summarized descriptively and reported only for patients with both prespacer and postspacer data available (10 THAs and 25 TKAs); no formal hypothesis testing was performed for ambulatory or functional measures. RESULTS: At 2 years of follow-up, the survival of the spacer free from unplanned reoperation or removal was 89% (95% confidence interval CI 80% to 99%) for patients with THA and TKA combined, the cumulative incidence of infection was 5% (95% CI 0% to 12%), and the Kaplan-Meier survivorship of the patients was 92% (95% CI 84% to 100%). The cumulative incidence of mechanical complications (spacer fracture or dislocation) was 5% (95% CI 0% to 13%). In the THA cohort (10 patients), ambulatory status before the first stage included two patients using a wheelchair, two using a walker, one using crutches, two using a cane, and three walking without assistive devices. At latest follow-up, four patients used a wheelchair, two used a walker, two used a cane, and two walked without assistive devices. In the knee cohort (25 patients), ambulatory status before the first stage included two patients using a wheelchair, five using a walker, 13 using a cane, and five walking without assistive devices. At latest follow-up, two patients used a wheelchair, five used a walker, 13 used a cane, and five walked without assistive devices. CONCLUSION: Retained articulating spacers can provide infection control in selected patients who do not proceed to reimplantation after first-stage spacer placement for PJI. Although infection-free spacer survival is achievable, these patients remain at risk for mechanical complications, including dislocation and fracture, as well as progressive functional decline. These risks should be clearly discussed during preoperative counseling to align expectations and support informed decision-making. Further studies are needed to refine patient selection, improve spacer durability, and standardize definitions of treatment success in PJI. LEVEL OF EVIDENCE: Level III, case series.
Sarfraz et al. (Fri,) studied this question.